Education
About Us
Working with TipRanks
Follow Us
Sinopharm Group Co Class H (HK:1099)
:1099
1099 Stock Chart & Stats
HK$20.28
-HK$0.15(-0.74%)
At close: 4:00 PM EST
HK$20.28
-HK$0.15(-0.74%)
Day’s Range― - ―
52-Week RangeHK$16.74 - HK$22.35
Previous CloseN/A
Volume3.49M
Average Volume (3M)4.72M
Market Cap
HK$62.54B
Enterprise ValueN/A
Total Cash (Recent Filing)HK$47.16B
Total Debt (Recent Filing)HK$93.29B
Price to Earnings (P/E)8.5
Beta0.77
Next Earnings
Mar 20, 2026EPS Estimate
1.26Last Dividend Ex-Date
Jun 16, 2025Dividend Yield3.7%
Share Statistics
EPS (TTM)0.65
Shares Outstanding1,341,810,800
10 Day Avg. Volume3,346,875
30 Day Avg. Volume4,718,690
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)0.79
Price to Sales (P/S)0.11
P/FCF Ratio6.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$21.47Price Target Upside5.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)2.54
Revenue Forecast (FY)HK$640.60B
Bulls Say, Bears Say
Bulls Say
Profit IncreaseNet profit for Sinopharm's Guoda pharmacy chain jumped 215.8% YoY.
Revenue GrowthRevenue from SPD (supply processing and distribution) and centrally procured contracts increased ~13% YoY.
Sales GrowthSame-store sales growth for Sinopharm's direct-to-patient pharmacies was >10% YoY, driven by innovative drugs.
Bears Say
Hospital Payment CyclesLengthening hospital payment cycles continue to weigh on the balance sheet with AR days increased 11 days YoY to 143 days.
Market EnvironmentRevenue decline was less severe than projected for the entire medtech segment, indicating a challenging market environment.
Operating Cash FlowOperating cash flow was a negative Rmb34.1bn in 1H25, versus a negative Rmb41.0bn in 1H24.
Sinopharm Group Co News
1099 FAQ
What was Sinopharm Group Co Class H’s price range in the past 12 months?
Sinopharm Group Co Class H lowest stock price was HK$16.74 and its highest was HK$22.35 in the past 12 months.
What is Sinopharm Group Co Class H’s market cap?
Sinopharm Group Co Class H’s market cap is HK$62.54B.
When is Sinopharm Group Co Class H’s upcoming earnings report date?
Sinopharm Group Co Class H’s upcoming earnings report date is Mar 20, 2026 which is in 97 days.
How were Sinopharm Group Co Class H’s earnings last quarter?
Sinopharm Group Co Class H released its earnings results on Oct 26, 2025. The company reported HK$0.65 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.65.
Is Sinopharm Group Co Class H overvalued?
According to Wall Street analysts Sinopharm Group Co Class H’s price is currently Undervalued.
Does Sinopharm Group Co Class H pay dividends?
Sinopharm Group Co Class H pays a Annually dividend of HK$0.739 which represents an annual dividend yield of 3.7%. See more information on Sinopharm Group Co Class H dividends here
What is Sinopharm Group Co Class H’s EPS estimate?
Sinopharm Group Co Class H’s EPS estimate is 1.26.
How many shares outstanding does Sinopharm Group Co Class H have?
Sinopharm Group Co Class H has 1,341,810,800 shares outstanding.
What happened to Sinopharm Group Co Class H’s price movement after its last earnings report?
Sinopharm Group Co Class H reported an EPS of HK$0.65 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.458%.
Which hedge fund is a major shareholder of Sinopharm Group Co Class H?
Currently, no hedge funds are holding shares in HK:1099
Sinopharm Group Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.12%
12-Months-Change
Fundamentals
Return on Equity
8.74%
Trailing 12-Months
Asset Growth
-0.78%
Trailing 12-Months
Company Description
Sinopharm Group Co Class H
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
1099 Stock 12 Month Forecast
Average Price Target
HK$21.47
▲(5.87% Upside)
Technical Analysis
Shanghai Pharmaceuticals Holding Co
―
IVD Medical Holding Limited
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---